ERBB2 and breast cancer: In particular, sub-analysis revealed that high mRNA expression of CBX6 was significantly associated with better survival in ER positive (HR=0.73, p=9e-07) (Figure 5B), HER-2 negative tumors (HR=0.73, p=2.7e-08) (Figure 5E), and Luminal A subtype patients (HR=0.69, p=1.7e-5) (Figure 5F), but not in HER-2 positive (HR=0.97, p=0.9) (Figure 5D), Luminal B subtype patients (HR=0.86, p=0.14) (Figure 5G), Basal-like subtypes BC patients (HR=1.02, p=0.89) or HER-2 subtype (HR=0.97, p=0.9) (Figure 5H, 5I).